Clinical Research in Southampton
Southampton Children's Hospital

A A A Text only | Accessibility | Privacy and cookies

Home
About the Trust
Our services
Patients and visitors
Our hospitals
Education
Research
Working here
Contact us

Browse site A to Z

A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z

Search results

Go To Simple Search

Search Type: Criteria:

You could also try: extend (164), delay (739), put off (233), lengthen (2), protract (5)

Tisacel-Cytarabine (500)-Etoposide (150)

Description: Chemotherapy Protocol CHIMERIC ANTIGEN RECEPTOR T-CELL (CAR-T) THERAPY ALL – TISACEL – CYTARABINE (500) – ETOPOSIDE (150) Regimen This regimen will only
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/ALL/Tisacel-Cytarabine-500-Etoposide-150.pdf

Brexucel - Cyclophosphamide (900) - Fludarabine (25)

Description: Chemotherapy Protocol CHIMERIC ANTIGEN RECEPTOR T-CELL (CAR-T) THERAPY ALL – BREXUCEL – CYCLOPHOSPHAMIDE (900) – FLUDARABINE (25) This regimen will only be
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/ALL/Brexucel-Cyclophosphamide-900-Fludarabine-25.pdf

Tisacel -Cyclophosphamide (250)-Fludarabine (25)

Description: Chemotherapy Protocol CHIMERIC ANTIGEN RECEPTOR T-CELL (CAR-T) THERAPY DLBCL/ FL – TISACEL – FLUDARABINE (25) – CYCLOPHOSPHAMIDE (250) Regimen This regimen will
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/Tisacel-Cyclophosphamide-250-Fludarabine-25.pdf

Tisacel-Bendamustine(90)

Description: Chemotherapy Protocol CHIMERIC ANTIGEN RECEPTOR T-CELL (CAR-T) THERAPY DLBCL/ FL – TISACEL – BENDAMUSTINE (90) Regimen This regimen will only be
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/Tisacel-Bendamustine90.pdf

Brexucel - Cyclophosphamide (500) - Fludarabine (30)

Description: Chemotherapy Protocol CHIMERIC ANTIGEN RECEPTOR T-CELL (CAR-T) THERAPY MCL – BREXUCEL – CYCLOPHOSPHAMIDE (500) – FLUDARABINE (30) This regimen will only be
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/Brexucel-Cyclophosphamide-500-Fludarabine-30.pdf

Axicel-Cyclophosphamide(500)-Fludarabine(30)

Description: Chemotherapy Protocol CHIMERIC ANTIGEN RECEPTOR T-CELL (CAR-T) THERAPY AXICEL – CYCLOPHOSPHAMIDE (500) – FLUDARABINE (30) This regimen will only be available
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/Axicel-Cyclophosphamide500-Fludarabine30.pdf

Durvalumab_14day

Description: Chemotherapy Protocol LUNG CANCER – NON-SMALL CELL (NSCLC) Durvalumab (14 day) Regimen • NSCLC - Durvalumab (14 day) Indication • Stage 3 NSCLC after
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lung-cancer-non-small-cellNSCLC/Durvalumab-14day.pdf

Durvalumab(28day-1500mg)

Description: Chemotherapy Protocol LUNG CANCER – NON-SMALL CELL (NSCLC) Durvalumab (28 day – 1500mg) Regimen • NSCLC - Durvalumab (28 day – 1500mg) Indication • Durvalumab is
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lung-cancer-non-small-cellNSCLC/Durvalumab28day-1500mg.pdf

Pembrolizumab2mg/kg

Description: Chemotherapy Protocol LUNG CANCER Pembrolizumab (2mg/kg) Regimen • NSCLC – Pembrolizumab (2mg/kg) Indication • Pembrolizumab is recommended as an option for treating
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lung-cancer-non-small-cellNSCLC/Pembrolizumab2mgkg.pdf

Nivolumab ver 1 (NSCLC)

Description: Chemotherapy Protocol LUNG CANCER – NON-SMALL CELL (NSCLC) Nivolumab This regimen may require funding. Regimen NSCLC – Nivolumab Indication Metastatic squamous non
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lung-cancer-non-small-cellNSCLC/Nivolumab-ver-1.pdf

21 to 30 of 164

Previous 1 2 3 4 5 … Next